Blebbistatin D-Ring Modifications for Soluble Myosin-2 Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel compounds that can selectively inhibit myosin 2 isoforms with improved solubility and mutagenicity compared to existing inhibitors, making them suitable for medical use.
Innovation Solution
Development of compounds of formula (I) and (II) that modify the D ring structure of blebbistatin, enhancing solubility and specificity for different myosin-2 isoforms such as skeletal, cardiac, smooth, and non-muscle myosin-2/NM2 A, B, C.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing myosin 2 inhibitors are used, then myosin 2 isoforms are inhibited, but solubility and mutagenicity are insufficient for medical use
Solution Approach 1:
The patent applies parameter changes by systematically modifying the D ring structure of blebbistatin with various substituents (halogens, alkyl groups, heterocyclic groups, etc.) to alter the physical and chemical properties of the inhibitor. These structural parameter changes improve solubility and reduce mutagenicity while maintaining myosin 2 inhibition effectiveness, resolving the contradiction between reliability and harmful factors.
Solution Approach 2:
The patent creates composite molecular structures by combining the core blebbistatin framework with diverse substituent groups at the D ring position. This composite approach allows the molecule to maintain its inhibitory function while acquiring improved solubility characteristics and reduced mutagenic properties through the combined effects of different structural elements.
2Adaptability or versatility
If myosin 2 inhibitors are developed for medical use, then therapeutic applications are enabled, but selectivity among different myosin-2 isoforms must be improved
Solution Approach 1:
The patent applies local quality by introducing specific substituents at the D ring position of the blebbistatin molecule, creating localized structural variations that differentially interact with specific myosin-2 isoforms. This local modification strategy enables selective inhibition of particular isoforms (such as NM2A, NM2B, or smooth muscle myosin) while preserving inhibition of others, achieving the required selectivity for targeted medical applications.
Solution Approach 2:
The patent systematically varies structural parameters at the D ring position (different heterocyclic groups, alkyl chains, halogen substitutions) to fine-tune the binding affinity and selectivity toward specific myosin-2 isoforms. These parameter changes allow optimization of the inhibitor profile for particular medical indications requiring isoform-specific action.
Data Source
AI summary
The present invention relates to compounds of formula (I) or (II)pharmaceutically acceptable salts, solvates, tautomers, stereoisomers thereof, including enantiomers, diastereomers, racemic mixtures, mixtures of enantiomers, or combinations thereof, and pharmaceutical uses of the compounds.